Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Dishman To Build $113 Million Plant For Anti-Cancer Drugs

This article was originally published in PharmAsia News

Executive Summary

Dishman Pharmaceuticals said it would invest $113.1 million in facilities in a pair of Indian economic zones where it has land. The firm said in filings with the Bombay Stock Exchange it intends to begin work in each of the zones by the end of this year. Separately, Dishman said it is in the process of constructing the largest facility in Asia, dedicated to high-potency drugs such as those to treat cancer. The facility is to be built in conjunction with its existing Bavla plant in Gujarat. (Click here for more
UsernamePublicRestriction

Register

SC069503

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel